Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients

Massimo Breccia; Michele Baccarani; Gianantonio Rosti; Francesco Cottone; Laura Cannella; François Guilhot; Marco Vignetti; Fabio Efficace

doi:10.1186/s12955-017-0788-4

Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients

Health Qual Life Outcomes. 2017 Oct 18;15(1):204. doi: 10.1186/s12955-017-0788-4.

Authors

Massimo Breccia¹, Michele Baccarani², Gianantonio Rosti², Francesco Cottone³, Laura Cannella³, François Guilhot⁴, Marco Vignetti³, Fabio Efficace⁵

Affiliations

¹ Department of Biotechnologies and Hematology, University of Rome Sapienza, Rome, Italy.
² Department of Hematology-Oncology, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy.
³ Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.
⁴ Inserm CIC 1402 , CHU de Poitiers, Poitiers, France.
⁵ Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy. f.efficace@gimema.it.

Abstract

We investigated factors that physicians consider of most importance in the selection of second line tyrosine kinase inhibitors treatments (TKIs) in chronic myeloid leukemia patients (CML).

Keywords: Chronic myeloid leukemia; Line of therapy; Tyrosine Kinase inhibitors.

Publication types

Letter

MeSH terms

Antineoplastic Agents / therapeutic use*
Attitude of Health Personnel*
Dasatinib / therapeutic use*
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Protein-Tyrosine Kinases / antagonists & inhibitors*
Pyrimidines / therapeutic use*
Quality of Life*

Substances

Antineoplastic Agents
Pyrimidines
Protein-Tyrosine Kinases
nilotinib
Dasatinib